A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Trial Profile

A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2015

At a glance

  • Drugs Motexafin gadolinium (Primary) ; Ibritumomab tiuxetan; Rituximab
  • Indications B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 26 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top